

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: Not classified	A2	(11) International Publication Number: WO 91/01624 (43) International Publication Date: 21 February 1991 (21.02.91)
(21) International Application Number: PCT/US90/04294 (22) International Filing Date: 31 July 1990 (31.07.90) (30) Priority data: 387,604 31 July 1989 (31.07.89) US (71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). (72) Inventor: LEE, Raphael C. ; 5000 South Greenwood Avenue, Chicago, IL 60615 (US). (74) Agents: OLEK, Alice. C. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With declaration under Article 17(2)(a). Without classification and without abstract; title not checked by the International Searching Authority.</i>
(54) Title: USE OF CALCIUM ANTAGONISTS FOR TREATING SCARS		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria
AU Australia
BB Barbados
BE Belgium
BF Burkina Faso
BG Bulgaria
BJ Benin
BR Brazil
CA Canada
CF Central African Republic
CG Congo
CH Switzerland
CM Cameroon
DE Germany, Federal Republic of
DK Denmark

ES Spain
FI Finland
FR France
GA Gabon
GB United Kingdom
GR Greece
HU Hungary
IT Italy
JP Japan
KP Democratic People's Republic
of Korea
KR Republic of Korea
LI Liechtenstein
LK Sri Lanka
LU Luxembourg

MC Monaco
MG Madagascar
ML Mali
MR Mauritania
MW Malawi
NL Netherlands
NO Norway
RO Romania
SD Sudan
SE Sweden
SN Senegal
SU Soviet Union
TD Chad
TG Togo
US United States of America

-1-

USE OF CALCIUM ANTAGONISTS FOR TREATING SCARSBackground of the Invention

A hypertrophic scar is an excessive wound scar which by definition has grown in size beyond that required for normal wound healing. Hypertrophic scars can emerge from many wound types, such as from a burn or a sharp incision. Keloids, a more severe form of hypertrophic wound scars, form firm dermal nodules of scar which are most commonly preceded by trauma at the site of origin. They are usually larger than hypertrophic scars and differ in that they frequently invade the normal skin adjacent to the wound.

Hypertrophic scars and keloids result from an over-production of cells, collagen and proteoglycan [Linares, H.A. and Larson, D.L., Plast. Reconstr. Surg., 62: 589 (1978); Linares, H.A., Plast. Reconstr. Surg., 818-820 (1983)]. Histologically, these lesions are characterized by randomly distributed tissue bundles consisting of uniaxially oriented extracellular matrix and cells. In these scars, the overproduction and compaction of collagen and proteoglycans [Shetlar, M.R. et al., Burns 4: 14 (1977)] exceeds the proliferation of cells. These histological observations suggest that the lesions result from loss of the normal control mechanisms which regulate the synthesis of extracellular matrix during wound healing [Shetlar, M.R. et al., Burns 4: 14 (1977)].

-2-

Existing therapy for hypertrophic scars and keloids, includes surgery, mechanical pressure, steroids, x-ray irradiation and cryotherapy. There are many disadvantages associated with each of these methods. Surgical removal of the scar tissue is often incomplete and can result in the development of hypertrophic scars and keloids at the incision and suture points. Steroid treatments are unpredictable and often result in depigmentation of the skin. X-ray therapy is the only predictably effective treatment to date; however, because of its potential for causing cancer, it is not generally recommended or accepted.

Compositions comprising tripeptides, tetrapeptides and pentapeptides have been shown to inhibit biosynthesis of collagen and may be used to treat diseases caused by excess accumulation of collagen (Mitsubishi Chem., Japanese Patent Nos. 52083545, July 12, 1977, and 52025768, February 25, 1977).

Recently, the effects of applying silastic sheets onto the surface of hypertrophic scars was studied and shown to shrink and soften scar tissue. [Ohmori, S. Aesthetic Plastic Surgery 12: 95-99 (1988)].

Despite various treatments presently available, there is no widely accepted and predictably effective means for preventing or treating hypertrophic scars or keloids.

Summary of the Invention

This invention pertains to a method for minimizing hypertrophic wound healing disorders, such as hypertrophic scars and keloids. Specifically, the method comprises administering an effective amount of a calcium channel blocking agent to a hypertrophic scar site for a period of time sufficient to minimize the wound or scar. Preferably, the calcium channel blocking agent is selected from verapamil, biologically compatible cobalt salts, such as cobalt chloride, and hydroxydipine compounds, such as nifedipine. The calcium channel blocking agent is applied to the wound site, such as by injecting it directly into a scar or topically applying it onto the wound site. In either case, the calcium channel blocking agent can be admixed with a pharmaceutically acceptable vehicle to facilitate localization of the agent to the wound site. The drug may be put into sustained release capsules to provide continuous treatment at therapeutic doses without systemic side effects.

This invention further pertains to a method for regulating and/or inhibiting exocytosis in fibroblast cells. The method comprises contacting fibroblast cells with an effective concentration of a calcium channel blocking agent sufficient to reduce exocytosis or even inhibit exocytosis.

The method of the present invention can be used to minimize hypertrophic wound healing disorders in humans. The method may also be used to treat other mammals. It can also be used to prevent formation of excessive tissue scarring. Alternatively, a calcium

channel blocking agent can be applied to a presently existing hypertrophic scar to reverse the scarring process and essentially eliminate the scar tissue. The present invention can also be used therapeutically to control diseases associated with excessive fibroblast biosynthesis, such as cirrhosis of the liver, constrictive pericarditis, Duputryen's disease of the hand, plantar fibrosis of the foot and various other fibromastosis.

10 Brief Description of the Figures

Figures 1a and 1b are graphic representations of the effects of antimycin A on protein incorporation into fibroblast populated collagen matrices (FPCM) bathed in DMEM/5.5 mM glucose and fructose, respectively.

Figure 2 is a graphic representation of the dose-dependent effect of verapamil on protein incorporation.

Figure 3 is a graphic representation of the effects of verapamil on sulfate incorporation into glycosaminoglycans.

Figure 4 is a graphic representation of the rate of exocytosis in human dermal fibroblasts in monolayer culture as a function of cellular fluorescence verses exposure time.

Figure 5 is a graphic representation of the retardation of exocytosis in human dermal fibroblasts caused by verapamil.

Detailed Description of the Invention

Calcium channels are regions of cell membranes which facilitate the transport and secretion of fluids and electrolytes, such as calcium, into the
05 cell [Rasmussen, H. N.E. J. Med. 314: 1094-1101 (1986)]. These channels can be blocked using a class of compounds known as calcium channel blockers, calcium entry blockers or calcium antagonists. Compounds included in this class are verapamil,
10 cobalt chloride and other biologically acceptable salts of cobalt, and hydropyridine compounds, such as nifedipine.

The present invention is based upon the discovery that calcium channel blocking drugs, which
15 block the transport of calcium across the cell membrane, can inhibit exocytosis in fibroblast cells; can retard biosynthesis of collagen and sulfated glycosaminoglycans (GAG); and can be used to decrease the collagen content of the extracellular
20 matrix.

Exocytosis is a process involved in cellular secretion of protein. During secretion, vesicles that contain sorted and concentrated protein pinch off from the Golgi apparatus and move toward the cell
25 membrane at the leading edge of the cell, where they fuse with the cell membrane and release protein into the extracellular space. This process of fusion and release is known as exocytosis and is an essential step in secretion of extracellular matrix macro-
30 molecules (such as glycosaminoglycans, collagen and elastin). Many diseases and disorders are brought about as the result of excessive biosynthesis. For example, hypertrophic wound healing disorders are

-6-

characterized by over-secretion of protein and collagen. The over-production results in excessive scarring or keloid formation.

As a result of the present discovery that
05 calcium channel blockers can inhibit exocytosis in fibroblasts, the invention can be used to prevent, minimize or even eliminate these hypertrophic wound healing disorders by reducing fibroblast secretion of protein and glycosaminoglycans. Fibroblast secretion
10 is blocked when exocytosis is inhibited. Likewise, other diseases in which the cells undergo excessive fibroblast secretion can be therapeutically controlled using the methods of this invention.

In a preferred embodiment, hypertrophic wounds
15 can be minimized by administering an effective amount of a calcium channel blocker to a hypertrophic wound site for a period of time sufficient to minimize the wound area. Suitable calcium channel blockers include, but are not limited to verapamil, biologically acceptable salts of cobalt, such as cobalt
20 chloride, and hydropyridine compounds, such as nifedipine. The amount of calcium channel blocker which can be effectively administered is dependent upon the type of calcium channel blocker used.
25 Threshold effective amounts of verapamil and nifedipine are approximately $10\mu\text{M}$ and $100\mu\text{M}$, respectively.

Hydropyridine compounds, such as nifedipine are relatively insoluble in aqueous solution. Due to

-7-

their insolubility, it may be advantageous to solubilize the drug in a non-polar carrier depending upon the location of the disorder to be treated. Calcium channel blockers can be administered to a wound site either alone or they can be admixed with pharmaceutically acceptable vehicles to facilitate their diffusion into the wound site. One suitable vehicle is dimethyl sulfoxide in a physiologically acceptable amount. Calcium channel blockers can be incorporated into liposomes.

Calcium channel blockers can be concentrated and incorporated into controlled release polymers as an alternative mode of administering the drug (e.g., transdermal administration). Examples of controlled release polymers have been described by Folkman and Langer, U.S. Patent No. 4,391,727, issued July 5, 1983; Yolles, U.S. Patent Nos. 3,880,991, issued April 29, 1975, and 3,887,699, issued June 3, 1975; Boswell, U.S. Patent No. 3,773,919, the teachings of which are incorporated herein by reference. Preferably, biodegradable polymers will be used.

The method of administering an acceptable dose of calcium channel blocker to minimize scarring is dependent upon the location of the hypertrophic wound and the extent of scarring. In particular, the calcium channel blocker, either alone or in combination with a pharmaceutically acceptable vehicle, can be topically applied to the surface of the wound site; it can be injected into the wound site, or it can be incorporated into a controlled release polymer and surgically implanted in a region to be treated.

Surgical implantation is advantageous for treating disorders such as cirrhosis of the liver and constrictive pericarditis. This permits the calcium channel blocker to be localized in the diseased site without adversely affecting the patient or releasing excessive amounts of the drug into the circulation system.

Exocytosis of fibroblast cells can be regulated or even prevented using the methods of this invention. In particular, fibroblasts are contacted with an effective amount of a calcium channel blocker sufficient to retard exocytosis to a desired degree. The method of contacting the calcium channel blockers to the fibroblast cells of interest and the effective amount of these drugs are described above.

In addition to treating hypertrophic wound healing disorders, calcium channel blockers can be used to therapeutically control diseases caused by excessive fibroblast biosynthesis. Diseases characterized by fibroblast overproduction include, cirrhosis of the liver, constrictive pericarditis, Dupuytren's disease of the hand as well as other fibromatosis. While these are but a few diseases which can be treated using the methods of this invention, it should be recognized that any disease which is characterized by excessive fibroblast biosynthesis can be treated using calcium channel blockers.

The invention is further illustrated by the following Examples.

Example 1Studies on Protein and GAG SecretionTissue Preparation

A connective tissue model of uniaxially oriented
05 cells and extracellular matrix was fabricated using
bovine fibroblasts, rat tail tendon collagen and
nutrient media. Bovine fascial fibroblasts were
harvested from the thigh of freshly slaughtered 2
week old calves (Trelegan's, Cambridge, MA) by
10 enzymatic digestion using 0.1% type II collagenase
(Worthington Biochemical Inc., Freehold, NJ) diges-
tion in Dulbecco's Modified Eagle Medium (DMEM; Gibco,
Grand Island, NY) at 37°C for 4 hours. The released
cells were seeded onto tissue culture dishes with
15 DMEM supplemented with 10% NuSerum (Collaborative
Research, Bedford, MA). The media was changed every
48 hours. The cells were passaged once and then
either used immediately or stored frozen in 50% calf
serum/45% DMEM/5% DMSO at -100°C. When frozen cells
20 were used they were quickly thawed, sedimented
through a column of 50% serum/50% DMEM at 185g for 3
minutes, then plated on coverslips. The media was
changed after cell attachment (~4 hours).

Native type I collagen was extracted from rat
25 tail tendon and purified using a modification of the
method of Chandrakasan, G. et al., J. Biol. Chem.
251:6062-6067 (1976). Specifically, rat tail tendons
were removed from adult Sprague-Dawley rat tails,
washed in PBS and distilled water. The tendons were
then placed in a solution of 0.05M (3%) acetic acid

-10-

at the ratio of 200ml per tail. The mixture was stirred for 96 hours at 8°C.

After 24 hours of stirring, the mixture was filtered through several layers of cheese cloth and then centrifuged at 12000g (9000 rpm in Sorval GS-3 rotor) for 2 hours. The supernatant was precipitated and redissolved in cold acid multiple times to remove non-collagenous proteins. The collagen solution was sterilized in 1/1000 v/v chloroform. This procedure preserves the native structure of the collagen molecule.

Oriented tissue equivalents were made by mixing bovine fibroblasts with a 0.2% collagen solution, 20% calf serum, 10mg/ml gentamycin solution, 5 mg/ml ascorbate in DMEM as previously described [McLeod, K.J. "Modulation of Biosynthesis by Physiologically Relevant Electric Fields" Ph.D Thesis M.I.T. 1986]. This suspension was poured into sterile culture dishes containing two sterile porous polyethylene posts held 2 centimeters apart. The dishes were placed in a cell culture incubator gassed at 5% CO₂ with 99% humidity. The suspension gelled at 37°C. Over several days, the fibroblasts remodelled and consolidated the collagen gel around the fixed posts. The resultant oriented fibroblast populated collagen matrix (FPCM) formed a tissue equivalent structure which histologically resembled a ligament. Oriented tissue equivalents are further described in U.S. Patent Application Serial No. 07/349,855, filed May 10, 1989, to R.C. Lee and D. Huang, the teachings of which are herein incorporated by reference.

Assay for Determining Biosynthetic Activity

Protein and glycosaminoglycan (GAG) biosynthesis was measured using radiolabeled precursors of protein and sulfated GAGs. Four days after casting of the

05 FPCM, the media bathing the ligament equivalents was changed to serum free DMEM with 0.5 mM L-proline (Sigma, St. Louis, MO). After 12 hours, the media was changed again to fresh serum-free media supplemented with 10 μ Ci/ml $\text{Na}_2^{35}\text{SO}_4$ (NEX-041, New England

10 Nuclear, Boston, MA), 10 μ Ci/ml L-[5- ^3H] proline (NET-573, New England Nuclear, Boston, MA) and 0.5 mM L-proline. The samples were bathed in the radiolabeled media for 12 hours. The radiolabeled sulfate was incorporated into GAGs and radiolabeled proline

15 into proteins, and so provide markers of sulfated GAGs and protein synthesis, respectively. Since DMEM is proline-free, the addition of non-radioactive proline ensures a relatively constant specific activity in the medium.

20 Effect of Calcium Channel Blockers on Biosynthesis

The effect of calcium channel blockers on protein and glycosaminoglycan (GAG) biosynthesis was measured in FPCMs under several conditions. The biosynthetic responses to calcium channel blockade

25 were studied in FPCMs cultured in DMEM supplemented with either 5 mM glucose or 5 mM fructose. Both were studied because energy metabolism of cultured fibroblasts is primarily anaerobic when the carbohydrate energy source is glucose and predominantly aerobic

-12-

when the carbohydrate source is fructose [Thilly, W. G., Mammalian Cell Technology, Chapter 5, Butterworth Publishers, Boston, (1986)]. In vivo fibroblasts are, however, believed to derive their energy primarily through aerobic glycolysis.

05 The drugs used to block calcium channels were verapamil, nifedipine and cobalt chloride. Control studies were performed to test the metabolic state of the cells in the FPCM. The effect of antimycin A, a
10 drug which blocks oxidative phosphorylation, on biosynthesis was measured in FPCMs cultured in fructose or glucose.

Results

Energy Metabolism

15 As previously reported [Thilly, W. G., Mammalian Cell Technology, Chapter 5, Butterworth Publishers, Boston, (1986)], differences between cellular energy metabolism of fibroblasts provided with glucose or fructose as energy substrates were observed. The
20 effects of antimycin A on both incorporation of proline into extracellular matrix protein and incorporation of sulfate into extracellular matrix glycosaminoglycans over a 12 hour period was measured in FPCMs bathed in DMEM/5.5 mM fructose and their
25 results are shown in Figures 1a and 1b, respectively. Antimycin A had little effect on proline incorporation with FPCMs provided with glucose. In contrast, antimycin A caused a substantial reduction in the rate of proline incorporation into the extracellular matrix in FPCMs provided with fructose.

Protein and Glycosaminoglycan Biosynthesis

When the effect of the carbohydrate source on the rate of biosynthesis of protein and glycosaminoglycan was examined in FPCMs bathed in DMEM/0.5 mM cold proline, no difference was observed between control FPCMs in glucose or fructose (Figure 2). There was a dose-dependent effect of verapamil on protein incorporation. However, the biosynthetic response to calcium channel blockaid was observed to depend on the type of calcium channel blocker used and whether the carbohydrate source was glucose or fructose.

Verapamil retarded the incorporation of proline into the extracellular matrix in the presence of either glucose or fructose (Figure 2). However, fibroblasts appeared to be more sensitive to verapamil when glucose was used as the metabolic energy source. Verapamil at 100 μ M concentration reduced the incorporation by almost 50% in FPCMs provided with either glucose or fructose. Verapamil had no significant effect on sulfated glycosaminoglycan biosynthesis, even at concentrations of 100 μ M (Figure 3). The lack of effect on GAG biosynthesis incorporation indicated that the verapamil did not reduce cell viability.

In equimolar concentrations, nifedipine caused a larger reduction of proline incorporation than verapamil. As for verapamil, nifedipine at 100 μ M concentration had no effect on GAG biosynthesis.

The rates of proline and sulfated glycosaminoglycan incorporation in fibroblast populated collagen matrices bathed in DMEM/5.5 mM glucose or fructose and a calcium channel blocker are shown in Table I.

05 50 mg/ml of cobalt chloride had a profound effect in reducing the rate of protein biosynthesis and increasing the rate of secretion of sulfated glycosaminoglycans, as compared with the effects of verapamil.

TABLE I

Rates of Incorporated Proline and Sulfate for Cultured Bovine Fibroblasts in FPCL in DMEM with Glucose or Fructose plus Calcium Channel Blockers

	Glucose (5.5mM)		Fructose (5.5mM)	
	Proline (cpm/1×10 ³ cells)	Glycosamino glycans sulfate (cpm/1×10 ³ cells)	Proline (cpm/1×10 ³ cells)	Glycosamino glycans sulfate (cpm/1×10 ³ cells)
Control	1.00 ± 0.04 (16)	1.00 ± 0.03 (16)	1.00 ± 0.05 (16)	1.00 ± 0.04 (16)
Verapamil (1μM)	0.85 ± 0.02 (16)	1.02 ± 0.03 (16)	1.02 ± 0.02 (16)	1.00 ± 0.04 (16)
Cobalt (50 ug/ml)	0.79 ± 0.01 (16)	1.14 ± 0.03 (16)	0.90 ± 0.03 (16)	1.01 ± 0.02 (16)

-15-

Example 2Studies on ExocytosisHuman Fibroblast Cell Culture

Human neonatal foreskin fibroblasts were harvested from newborns at the time of circumcision at the Brigham and Woman's Hospital. The samples were initially placed in antibiotic supplemented Dulbecco's Modified Eagles Media (DMEM) then incubated in trypsin for 20 minutes to remove the surface epithelial layer. The tissue was then washed in Phosphate-Buffered Saline (PBS) solution, then centrifuged at 180g for 5 minutes to separate the epidermal cells. The dermis was minced then subjected to 0.1% type II collagenase (Worthington Biochemical Inc., Freehold, NJ) digestion in DMEM for 4 hours. The released cells were seeded onto tissue culture dishes with DMEM supplemented with 10% NuSerum (Collaborative Research, Bedford, MA). The media was changed every 48 hours. The cells were passed once and then were either used immediately or stored frozen in 50% serum/45% DMSO at -100°C. When frozen cells were used they were quickly thawed, sedimented through a column of 50% serum/50% DMEM at 185g for 3 minutes, then plated on coverslips. The media was changed after cell attachment (~4 hours).

Quantification of Dye Release

To determine if the rate of fluid phase exocytosis was modulated by calcium channel blockers, the rate of exocytosis in human fibroblasts was

-16-

measured using the rate of release of Lucifer yellow labeled dextran (LYD, M.W. 10,000) (Molecular Probes Inc., Portland, Oregon), from vesicles in the cytoplasm of human foreskin fibroblasts. The LYD was
05 loaded into cells by fluid phase pinocytosis (endocytosis) in the absence of serum. The intracellular location and transport of the dye was monitored under control and experimental conditions using video image analysis.

10 P₂ - P₅ fibroblast cells were harvested from monolayer by brief 1x trypsin and ethylenediamine-tetraacetic acid (EDTA) digestion, plated on glass coverslips and allowed to become 50% confluent. Cell
15 laden coverslips (CLCS) were bathed in DMEM supplemented with 5 mg/ml Lucifer Yellow CH Dextran (LYD) for 12 hours under standard conditions. The CLCS were then washed five times in PBS at 37°C to remove extracellular LYD, then placed in 60 mm sterile cell culture dishes. The dishes contained serumfree DMEM
20 at 37°C supplemented with either verapamil (10 µM), or no drug (control). The dishes were returned to the 5% CO₂ gassed incubator. Two CLCS were removed from each of the dishes after 0, 2, 4 and 6 hours. They were quickly immersed in neutral buffered
25 formalin at 8°C allowed 20 minutes to fix, then the CLCS were mounted on glass microscope slides. The mounting solution was 50% glycerol, NaF phenyl-aminodiamine.

-17-

Each cell to be analyzed was placed in the center position within the field of view. The LY fluorescence was excited by filtered 100 watt mercury arc lamp illumination. The excitation was filtered
05 with an interference filter with a bandpass of 460-485 nm. The emission was collected with a 40x objective and passed through a 515 nm barrier filter. The emission was recorded with a video camera head with a chalnicon tube, digitized and stored by a
10 Hamamatsu video image processor under the control of a VaxStation II computer. This procedure was repeated under phase illumination so that the boundaries of the cell could be accurately identified by phase contrast. A software program located the
15 boundaries of the cell by identifying pixels with intensity values more than two standard deviations below the mean background pixel intensity in a manually chosen background area.

To quantify the average intensity in the cell cytoplasm, the mean background value (B_m) was subtracted from the entire image including the pixel
20 values in the cell (P_i). Since the background intensity could be used as a measure of the excitation intensity, the net pixel values within the boundaries of the cell were normalized to B_m . The
25 normalized pixel values were then summed, and that sum was normalized to the area of the cell (A). This result was termed the intensity of the cell I_c :

$$I_c = \sum_i (P_i - B_m) / B_m A$$

-18-

I_c was determined for each of the 50 cells, 25 from each of two simultaneously-removed coverslips. The standard deviation and means were then calculated. The mean for two coverslips was plotted at each time point (2, 4 and 6 hours). This process was carried out for both the experimentals and controls at each time point.

Results

10 Exocytosis

Exocytosis was observed to proceed at a near constant rate over a six hour period of observation in human dermal fibroblasts in monolayer culture (Figure 4). The rate of exocytosis of Lucifer yellow dextran was found to be sensitive to plasma membrane calcium channel function. Both verapamil (10 μ M) and nifedipine (100 μ M) were found to significantly retard exocytosis over a six hour period in these cells (Figure 5 and Tables II and III). These results clearly demonstrate that exocytosis in human fibroblasts can be regulated. In Figure 5, the controls are represented by the filled circles and verapamil is represented by the squares. Tables II and III show the retardation of exocytosis in human dermal fibroblasts by calcium channel blockers, verapamil (50 μ M) and nifedipine (1 μ M), respectively.

-19-

TABLE II

Effect of Verapamil on Exocytosis Response

Stimulus	Exposure Time (hours)	Average Intensity	Standard Error	Intensity Difference	p value
Control	0	855	38		
	6	691	23		
Verapamil: 50 μ M	6	793	35	14.8%	p<0.02

TABLE III

Effect of Nifedipine on Exocytosis Response

Stimulus	Exposure Time (hours)	Average Normalized Intensity	Standard Error	p value
Control	0	.58	.029	
	4	.54	.029	
	6	.36	.015	
Nifedipine: 1 μ M	4	.58	.029	p>0.05
	6	.49	.047	p<0.03

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific
05 embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.



-21-

CLAIMS



1. A method for treating hypertrophic wound healing disorders, comprising administering an effective amount of a calcium channel blocker locally to a hypertrophic scar site for a period of time sufficient to minimize or essentially eliminate the wound.
05
2. The method of Claim 1 wherein the calcium channel blocker is admixed with a pharmaceutically acceptable vehicle.
10
3. The method of Claim 2 wherein the calcium channel blocker is selected from the group consisting of nifedipine, hydroxydipine, verapamil, cobalt chloride and biologically acceptable salts of cobalt.
15
4. The method of Claim 1 wherein the step of administering is by injecting the calcium channel blocker into the wound.
5. The method of Claim 1 wherein the step of administering is by topically applying the calcium channel blocker onto the scar.
20
6. The method of Claim 1 wherein the step of administering is by incorporating the calcium channel blocker into a controlled releasing polymer.



-22-



- 05 7. A method for treating fibromastosis, comprising administering an effective amount of a calcium channel blocker locally to a fibromastosis for a period of time sufficient to minimize or essentially eliminate the fibromastosis.
8. The method of Claim 7 wherein the calcium channel blocker is admixed with a pharmaceutically acceptable vehicle.
- 10 9. The method of Claim 7 wherein the calcium channel blocker is selected from the group consisting of nifedipine, hydropyridine, verapamil, cobalt chloride and biologically acceptable salts of cobalt.
- 15 10. The method of Claim 7 wherein the step of administering is by injecting the calcium channel blocker into the fibromastosis.
11. The method of Claim 7 wherein the step of administering is by topically applying the calcium channel blocker onto the fibromastosis.
- 20 12. The method of Claim 7 wherein the step of administering is by incorporating the calcium channel blocker into a controlled releasing polymer.

*Fig. 1a**Fig. 1b*

SUBSTITUTE SHEET

*Fig. 2a**Fig. 2b*

*Fig. 3a**Fig. 3b*

*Fig. 4**Fig. 5*

SUBSTITUTE SHEET

PATENT COOPERATION TREATY

DECLARATION OF NON-ESTABLISHMENT OF INTERNATIONAL SEARCH REPORT

Issued pursuant to PCT Article 17(2) (a) ⁽¹⁾

IDENTIFICATION OF THE INTERNATIONAL APPLICATION PCT/US 90/04294	APPLICANT'S OR AGENT'S FILE REFERENCE MIT-5011
International Application No. PCT/US 90/04294	International Filing Date 31st July 1990
Receiving Office RO/US	Priority Date Claimed 31st July 1989
Applicant (Name) MASSACHUSETTS INSTITUTE OF TECHNOLOGY	

DECLARATION

This International Searching Authority hereby declares that no international search report will be established on the above-identified international application for the reasons indicated below. (1)

1. The subject matter of the international application relates to: (2)

- a. ☐ scientific theories.
- b. ☐ mathematical theories.
- c. ☐ plant varieties.
- d. ☐ animal varieties.
- e. ☐ essentially biological processes for the production of plants and animals, other than microbiological processes and the products of such processes.
- f. ☐ schemes, rules or methods of doing business.
- g. ☐ schemes, rules or methods of performing purely mental acts.
- h. ☐ schemes, rules or methods of playing games.
- i. ☒ methods for treatment of the human body by surgery or therapy.
- j. ☒ methods for treatment of the animal body by surgery or therapy.
- k. ☒ diagnostic methods.
- l. ☐ mere presentations of information.
- m. ☐ computer programs for which this International Searching Authority is not equipped to search prior art.

2. The failure of the following parts of the international application to comply with prescribed requirements prevents a meaningful search from being carried out: (3)

- a. ☐ the description.
- b. ☐ the claims.
- c. ☐ the drawings.

comment:

CERTIFICATION

International Searching Authority ISA / EP	Date of Mailing 14. 11. 90	Authorized Officer F.W. HECK <i>Reck</i>
--	--	--

THIS PAGE BLANK (USPTO)